Background: Data are inconclusive whether treatment with HAART induces functional recovery of HIV-specific T-cells. Since the introduction of HAART, a marked decrease of cytomegalovirus (CMV) disease -for which untreated HIV-infected individuals are at increased risk -is observed, suggesting that this treatment influences CMV-specific T-cell immunity. Methods: To study potential functional recovery of HIVand CMV-specific T-cells, CD4
+ and CD8 + T-cell responses were measured longitudinally after in vitro expansion using gag, pp65 and IE1 peptide pools, during HIV infection and after long-term HAART. Results: HIV-specific T-cell function, measured by interferon (IFN)-γ production, was low after initiation of HAART. Interestingly, the cytotoxic function -measured by CD107a expression -of these T-cells temporarily increased after start of treatment, suggesting some functional recovery. The pp65-specific CD8 + T-cell responses tended to decrease during HIV infection, whereas pp65-specific CD4 + T-cell responses decreased upon treatment with HAART. Both pp65-specific CD4 + and CD8 + T-cell responses were low after initiation of HAART compared to healthy controls. By contrast, IE1-specific CD4 + T-cell responses increased during the course of HIV infection. After initiation of HAART, IE1-specific T-cell responses decreased, but IE1-specific CD8 + T-cells seemed increased compared to healthy controls. Conclusions: This study suggests that HIV-infection leads to an altered CMV biology, affecting pp65-and IE1-specific T-cell responses in a different way, which is not restored by treatment with long-term HAART.
The introduction of HAART changed the course of HIV infection dramatically and resulted in clinical benefits for infected individuals. HAART decreased HIV replication and increased CD4 + T-cell counts [1] [2] [3] . As a result of successful treatment, HIV-specific T-cell responses were shown to decrease after initiation of HAART [4] [5] [6] . Two aspects may influence the outcome of HIV-specific T-cell responses after HAART. Due to successful treatment, HIV load will decrease, resulting in decreased HIV-specific T-cell stimulation which will lead to decreased HIV-specific T-cell numbers [7, 8] . By contrast, a decrease in HIV load and subsequent decrease in immune activation may lead to functional recovery of HIV-specific T-cells, as T-cell function decreases in HIV infection due to persistent high antigen exposure [9] . Because of this subtle balance, potential functional recovery may result in only a slight increase in HIVspecific T-cell responses.
HAART also reduces the incidence of opportunistic infections, including cytomegalovirus (CMV) [10] . The incidence of CMV retinitis -which is the most common manifestation of CMV disease in HIVinfected individuals -decreased by approximately 80% after the introduction of HAART [11] . Risk factors for CMV retinitis are CD4 + T-cell count <100 cells/mm 3 and HIV load >10,000 copies/ml [12] . In addition, increased CMV loads were shown to precede development of CMV disease [13] . Furthermore, CMV-specific interferon (IFN)-γ production by CD4 + and CD8 + T-cells have been shown to be low or
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Influence of HIV infection on cytomegalovirusspecific immunity: T-cell responses to pp65 and IE1 before and after HAART may reflect altered cytomegalovirus biology Introduction absent in patients developing CMV disease [13, 14] . These findings suggest an important role for IFN-γ-producing CD4 + and CD8 + T-cells in control of CMV replication. Treatment with HAART was shown to result in restoration of specific immunity to opportunistic infections, including CMV. Indeed, restoration of CMV-specific CD4 + T-cell proliferative capacity was seen approximately 5 years after initiation of HAART [4] . By contrast, IFN-γ production by CMV-specific CD4 + T-cells decreased as measured directly ex vivo after 6 h of stimulation [4, 15] . Furthermore, CD8 + T-cell responses to the immediate early antigen (IE1) were reported to be increased in HIV-infected individuals on HAART compared to healthy controls, whereas such differences were not observed for T-cells to the tegument protein pp65 [16] . A previous study showed different kinetics of T-cell responses directed against a latent and a lytic protein derived from Epstein-Barr virus (EBV) during HIV infection and subsequent treatment with HAART [17] . In line with these findings, T-cell responses directed against pp65 and IE1 might also have different kinetics during HIV infection and after initiation of treatment with HAART.
Until now, HIV-specific T-cell responses have mostly been measured using intracellular cytokine staining and ELISpot assays after stimulation with HIV-specific peptides [18] [19] [20] and HLA class I tetramer staining [8, 21] . As HIV-specific T-cell numbers become very low after successful treatment with HAART, the detection of these specific T-cells becomes difficult with the traditional assays. Recently a highly sensitive assay was developed, enabling the detection of low frequency antigen-specific T-cells [22] . The read out of this system consists of a combination of the proliferative capacity and the ability of the antigen-specific memory T-cells to differentiate to cytokine producing effector T-cells. In the present study CMV-and HIVspecific T-cell responses were longitudinally measured by means of this sensitive assay. We studied functional recovery of antigen-specific T-cells, as well as potential differences in kinetics between pp65 and IE1-specific T-cells during chronic HIV infection and after initiation of HAART.
Methods

Study population
A total of 10 HIV-seropositive men participating in the Amsterdam Cohort Studies on HIV infection and AIDS (ACS) were included in this study. Patients were selected based on availability of material. None of the 10 included individuals were diagnosed with an AIDSdefining event. Patients were studied early in infection (median 14 months after seroconversion; T1), late in HIV infection, but before initiation of treatment with HAART (median 86 months after seroconversion; T2), early after the start of HAART (median 15 months after start of HAART; T3) and long after the start of HAART (median 65 months after start of HAART; T4). HAART was defined by a treatment regimen consisting of at least two nucleotide or nucleoside reverse transcriptase inhibitors (NRTIs) and one protease inhibitor (PI) or one NRTI and two PIs. Patient characteristics are indicated in Table 1 . In addition, 10 healthy CMV-seropositive blood bank donors were included. Informed written consent was obtained from all participants of the ACS and blood bank donors.
Analysis of lymphocyte markers by flow cytometry
Analyses of programmed death-1 (PD-1) expression on lymphocytes were performed using multicolour fluorescence flow cytometry. 
T-cell stimulation
Antigen-specific T-cell expansion
To expand the number of CMV and HIV-specific T-cells, PBMC were cultured for 12 days in the presence of CMV or HIV overlapping peptide pools, as described previously [22] . PBMC were thawed and incubated at 37°C, 5% CO 2 in U-shaped 96-well plates (2×10 5 PBMC/well and 1.5×10 6 PBMC total) together with peptide pool of pp65, IE1 or gag. Culture medium consisted of RPMI 1640 (Gibco, Life Technologies, Breda, the Netherlands) supplemented with 10% human pool serum and 1% penicillin/streptomycin. On day 0 and 6 peptide pool was added (2 µg/ml) and at days 2, 6 and 8 PBMC were supplemented with 10 U/ml interleukin (IL)-2 [23] . After 12 days PBMC were pooled and rested overnight without peptide pool or IL-2. On day 13, PMBC were restimulated with peptide pool (1 µg/ml). CD28 (1 µg/ml) and CD49d (1 µg/ml) were added for costimulation. CD107a-FITC (40 µl/ml; Becton Dickinson) was added directly to the PBMC. After 1.5 h monensin (0.67 µl/ml) was added (Golgistop; BD Biosciences, San Jose, CA, USA) and PBMC were incubated for another 4.5 h. As a negative control PBMC were stimulated with medium and costimulation alone. As a positive control, PBMC were stimulated with PMA (10 ng/ml) and ionomycin (2 µg/ml). Afterwards, PBMC were washed with PBS plus 0.5% bovine serum albumin, and stained with CD3-Pacific Blue, CD8-PerCP (Becton Dickinson) and CD4 Alexa Flour 750 (eBioscience, San Diego, CA, USA) for 20 mins. Subsequently cells were washed and permeabilized (FACS Permeabilizing Solution and FACS Lysis Solution; Becton Dickinson), washed again and stained with IFN-γ-PE Cy7 (Becton Dickinson Pharmingen, San José, CA, USA). Cells were washed, fixed (Cellfix; Becton Dickinson) and ≥200,000 cells were acquired by the LSRII flow cytometer (Becton Dickinson). Based on the forward and sideward scatter, lymphocytes were gated and data were analysed by FACSDiva software (Becton Dickinson). For measurement of IFN-γ and CD107a, the percentage of responding T-cells was calculated after subtraction of the negative control values.
Plasma HIV-1 RNA determination
Plasma HIV-1 RNA was measured by the NucliSens HIV-1 QT assay (bioMérieux, Boxtel, the Netherlands) with a detection limit of 1,000 copies/ml or Amplicor HIV monitor (Roche Diagnostic Systems Inc., Branchburg, NJ, USA) with a detection limit of 400 copies/ml. The more sensitive Quantiplex bDNA 3.0 assay (Bayer Corporation, Tarrytown, NY, USA) with a detection limit of 50 copies/ml was used after August 1999.
Statistical analysis
Statistics were computed by SPSS 15.0 for Windows (SPSS, Inc., Chicago, IL, USA). The Wilcoxon signed-rank test was used for analysis of differences over time. Potential differences between HIV-infected patients and healthy controls were analysed by MannWhitney U tests. Correlations were calculated using Spearman's correlation test. P-values <0.05 were considered significant.
Results
Effect of HAART on PD-1 expression
Treatment with HAART induced a decrease in HIV plasma RNA concentration from a median of 20,000 copies/ml late in HIV infection to undetectable levels during HAART (P=0.005; Table 1 ). Both CD4 + (P=0.037) and CD8 + (P=0.050) T-cell counts increased after HAART and as we previously showed, expression of HLA-DR and CD38 -which had increased during HIV progression -decreased upon treatment with HAART [17] . Here we investigated expression of the exhaustion marker PD-1, which was shown to be affected by antigen exposure [24] . Within 1 year after initiation of HAART, PD-1 expression on CD4 + T-cells (P=0.041; Figure 1A ) and CD8 + T-cells (P=0.022 and P=0.021 compared to early and late in HIV infection, respectively; Figure 1A ) was reduced, suggesting a marked influence of HIV RNA load on the expression of PD-1. In contrast to activation markers on CD4 . Together these data indicate that treatment with HAART was successful in this study population and that PD-1 expression can be used as a marker for immune activation. Given the fact that immune activation is associated with progression to (HIV) disease, these markers of immune activation actually are indicative of immune dysfunction in chronic viral infections.
Effect of HAART on IE1-specific CD8 + T-cell responses
To determine the effect of HAART on the functional capacity of CMV-specific T-cells, IFN-γ production was measured after in vitro expansion and stimulation with overlapping peptide pools of pp65 and IE1, as described previously for EBV [22] . This assay measures the ability of antigen-specific T-cell to survive and proliferate and drives T-cells towards an effector memory phenotype during a 12-day culture period (JS et al., unpublished observations). We have previously shown that this assay specifically detects memory T-cells, as no responses are detected after culture of cord blood cells [22] . Figure 2A shows representative CD4 + T-cell responses after 12-day culture and restimulation with IE1-peptide pool. Compared to healthy individuals, IE1-specific CD4 + T-cell responses were high late in HIV infection (P=0.015). These responses were significantly decreased after initiation of HAART (shortand long-term after start of HAART P=0.036 and P=0.028, respectively; Figure 2B ). Although not statistically significant, IE1-specific CD4 + T-cell responses remained slightly increased compared to healthy controls after HAART.
Similar to IE1-specific CD4 + T-cell responses, IE1-specific CD8 + T-cell responses were increased during HIV infection compared to healthy individuals (early and late during HIV infection, P=0.016 and P<0.001, respectively; Figure 2C ). Upon treatment with HAART, IE1-specific CD8 + T-cell responses decreased (late in HIV infection compared to long term HAART, 
P=0.028), but still remained increased compared to healthy controls.
Pp65-specific T-cell responses after initiation of HAART
Pp65-specific CD4
+ T-cell responses remained relatively stable during the course of HIV-infection. After initiation of HAART, however, IFN-γ production by pp65-specific CD4 + T-cells decreased (short-and long-term after start of HAART P=0.028 and P=0.017, respectively; Figure 2D ). Also, compared to healthy controls, pp65-specific CD4 + T-cell responses were significantly lower after initiation of HAART (P=0.016 and P=0.033, respectively). In contrast to CD4 + T-cell responses, pp65-specific CD8 + T-cell responses changed neither during HIV infection, nor after start of HAART (Figure 2E) , although late in HIV infection and during treatment with HAART, pp65-specific CD8 + T-cell responses tended to be lower compared to healthy controls.
Besides the ability to produce IFN-γ, the capacity of memory CD8 + T-cells to degranulate after 12 days expansion was also analysed by mobilization of CD107a during antigen-specific re-stimulation. Expression of CD107a is a measure for potential cytotoxic capacity. The pattern of expression of CD107a was comparable to the expression of IFN-γ by pp65-and IE1-specific CD8 + T-cells (JS et al., data not shown).
Gag-specific T-cell responses during HIV infection and treatment with HAART
HIV-specific CD4 + and CD8 + T-cell responses were measured by stimulation with gag overlapping peptide pool. Figure 3A shows representative FACS plots of IFN-γ production and CD107a expression by CD8 + T-cells after restimulation. No significant changes in IFN-γ production by gag-specific CD4 + or CD8 + T-cells could be observed ( Figure 3B ), although gag-specific CD8 + T-cell responses tended to decrease after initiation of HAART.
We next investigated the cytotoxic function -measured by CD107a expression -of IFN-γ producing CD8 + T-cells increased markedly early after initiation of HAART (P=0.028; Figure 3C ). Long-term after start of HAART, this effect disappeared.
Discussion
In this study we investigated CMV-and HIV-specific immunity in the course of HIV infection and the influence of treatment with HAART, using a highly sensitive assay which measures antigen-specific T-cell responses after prolonged stimulation.
Previous studies, using assays to measure IFN-γ production directly ex vivo, observed a decrease in IFN-γ production by HIV-specific CD4 + and CD8 + T-cells after start of HAART [4] [5] [6] . HIV-specific CD4 + T-cell responses were reported to be decreased 7.5 months and 55 months after initiation of HAART [4] . Only 4-24 weeks after initiation of HAART, HIV-specific CD4 + T-cell responses tended to decrease and 47-112 weeks after the start of HAART, HIV-specific CD4 + T-cell responses were hardly detectable in a study by Pitcher et al. [6] In addition, decreased HIV-specific CD8 + T-cell responses 6 months after the start of HAART were reported by Ogg et al. [5] . However, Kostense et al. [18] reported a decrease in HIV-specific T-cell numbers (average of 3 and 6-15 months after the start of HAART), but an increase in the percentage of IFN-γ-producing HIV-specific CD8 + T-cells. This suggests that timing and the assay used for detection of antigen-specific T-cells may be very important. In this study, although HIV-specific T-cells gained additional function, as indicated by increased CD107a expression by IFN-γ + CD8 + T-cells, IFN-γ producing HIV-specific T-cell frequencies were still very low after initiation of HAART. We cannot exclude, however, that our T-cell analyses were performed too late in these patients (1 year after initiation of HAART) to observe functional restoration.
PD-1 expression, which is linked to negative regulation of T-cell proliferation, activation and cytokine production [26, 27] , was decreased upon treatment with HAART on CD4 + and CD8 + T-cells and correlated with expression of HLA-DR and CD38. This finding is in accordance with previous studies [24, 28] . Correlation between PD-1 expression and HIV RNA load indicates upregulation of PD-1 due to presence of high antigen load, as reported previously [29, 30] . PD-1 expression on both CD4
+ and CD8 + T-cells also correlated inversely with CD4 + T-cell numbers. Although patient numbers were limited in this study, differences between IE1 and pp65-specific T-cell responses were observed. After initiation of HAART, IFN-γ production by CMV-specific CD4 + T-cells decreased. pp65-Specific CD4 + T-cell responses were significantly lower compared to controls, and pp65-specific CD8 + T-cells showed a comparable trend. However, pp65-specific CD8 + T-cells already tended to decrease during chronic HIV infection. By contrast, IE1-specific CD4 + and CD8 + T-cell responses were increased during chronic HIV infection compared to healthy individuals. After initiation of HAART IE1-specific T-cell responses decreased but remained slightly increased compared to healthy individuals. In a large cross-sectional study, Naeger et al. [31] recently observed that the proportion of CMV-specific CD8 + T-cells was consistently higher in HIV-infected individuals compared to HIV-negative healthy controls. At first glance, this is in disagreement with our data, as we observed lower pp65-specific T-cell responses in HIV-infected individuals compared to healthy controls. One explanation for the difference in outcome could be the use of a different assay, as our assay measures the ability of antigen-specific T-cells to survive and proliferate and drives T-cells towards an effector memory phenotype during a 12-day culture period. Therefore, a difference in proliferative capacity between healthy controls and HIV-1-infected individuals could be the underlying mechanism for the observed difference. However, since our study, as well as the study by Naeger et al. [31] , show increased IE1-specific T-cells in HIV-infected individuals compared to healthy controls, a more likely explanation might be the choice of HIV-1-negative individuals. In the present study we included 10 healthy CMV-seropositive blood bank donors. Naeger et al. [31] , however, included both HIV-uninfected but at-risk participants as well as HIV-seronegative adults responding to advertisements. Furthermore, differences in CMVspecific T-cell responses during the course of HIVinfection and treatment between the two studies can very well be explained by the type of study, as Naeger et al. [31] performed a cross-sectional study, whereas we performed a longitudinal study.
Our results are in accordance with a study by Stone et al. [16] who reported increased frequencies of IE1-specific CD8 + T-cells in patients on HAART compared to healthy individuals. We now show that IE1-specific T-cell responses already increased during untreated HIV infection and that these increased T-cell numbers are not caused by HAART treatment. Increased IE1-specific T-cell responses during chronic HIV infection might reflect increased rates of CMV replication. Since IE1 is one of the genes which is expressed very early after initiation of CMV replication, it is expected that an increase in viral replication and gene expression will be first reflected by T-cell responses directed towards this protein. However, this increased initiation of replication does not result in high levels of CMV load as previous data showed that a detectable CMV load is only present a few months before development of CMV disease, whereas CMV load is not detectable during HIV infection [13] . This is in contrast to EBV reactivation during HIV infection, which does lead to high levels of EBV DNA load in the blood [32] . In addition, increased IE1-specific T-cell responses might be caused by oligoclonal expansion of a restricted number of CMV-specific T-cells. During chronic HIV infection a decrease in T-cell receptor diversity occurs [33] . Presumably, oligoclonal expansion of IE1-specific T-cells occurs more frequently than oligoclonal expansion of pp65-specific T-cells, due to increased initiation of CMV viral replication during chronic HIV infection. This may result in increased frequencies of IE1-specific T-cells and decreased frequencies of pp65-specific T-cells compared to healthy controls. Furthermore, T-cell receptor diversity is not increased upon treatment with HAART [34] , which might explain the endurance of low frequency of pp65-specific T-cells during treatment with HAART.
Another explanation for high IE1-specific T-cell responses may be that these responses are important for the control of CMV viral replication. In line with these findings Bunde et al. [35] suggested a role for IE1-specific CD8 + T-cell responses in protection against CMV disease in heart and lung transplant patients. Since pp65-specific CD8 + T-cell numbers do not significantly change during HIV infection [36] , the decrease in pp65-specific T-cell responses might represent a decrease in function rather than a decrease in pp65-specific T-cell frequencies. However, the decrease in pp65-specific T-cell responses appeared not to be harmful, as none of these HIV patients developed CMV disease.
Based on the results of the current study, we propose the following model for dynamics of CMV-specific immunity during HIV-1 infection and treatment with HAART (Figure 4) . Presumably HIV infection leads to increased CMV replication, although viral load generally remains too low to be detectable [37] . Increased replication leads to increased CMV-specific T-cell responses, as observed by increased IE1-specific T-cell responses during chronic HIV infection. This is in line with increased frequencies of EBV-specific T-cells directed against an EBV immediate early antigen after HIV-infection. Decreased pp65-specific T-cell responses may indicate that either pp65-specific T-cell responses play a minor role or that infection with HIV affects these specific T-cell responses as their functional capacity decreases during HIV-infection. Both pp65 and IE1-specific T-cell responses decrease after initiation of HAART, which may indicate a reduction in CMV replication. This is in accordance with previous literature in which HIV-infected patients with high CMV viral load were shown to benefit from HAART, indicated by a decrease in CMV viral load upon treatment [38, 39] . Control of CMV viral replication due to HAART is also reflected by the decreased incidence of CMV disease after the introduction of HAART [11] . IE1-specific T-cell responses decreased after the start of HAART and reached levels comparable to those in healthy controls. In contrast, pp65-specific T-cell responses were below the level of healthy controls after initiation of HAART. This indicates that treatment with HAART does not restore pp65-specific T-cell function and that the altered CMV biology induced by HIV infection remains.
In conclusion, the hierarchy of pp65-and IE1-specific T-cell responses is different in HIV-infected individuals compared to healthy controls. This suggests that HIV infection may alter the biology of CMV infection. In healthy individuals, cytomegalovirus (CMV) replication is low and CMVspecific T-cell responses are dominated by pp65-specific T-cell responses. Upon HIV infection, initiation of CMV replication occurs more frequently. pp65-Specific T-cell responses tend to decrease, whereas IE1-specific T-cell responses increase and become dominant. After initiation of HAART, the frequency of CMV replication reduces again, which results in decreased IE1-specific T-cell responses. In contrast, HAART does not restore pp65-specific T-cell responses. Timepoint of HIV infection and initiation of HAART are depicted by a straight vertical line and a dashed vertical line, respectively.
